MOST NOTEWORTHY: AeroVironment, American Oriental and Intel were today's noteworthy initiations:

• Suntrust initiated AeroVironment (NASDAQ: AVAV) with a Buy rating and $32 target and expects AVAV's market leadership in unmanned aerial systems and increased effort in the high altitude to drive strong organic growth.
• Jefferies believes American Oriental (NYSE: AOB) is capable of making sizable acquisitions given its strong cash position and finds the valuation attractive at current levels. The firm started shares with a Buy rating and $20 target.
• Intel (NASDAQ: INTC) was initiated with a Neutral rating and $30 target at Baird on valuation.

OTHER INITIATIONS:

• Equinix (NASDAQ: EQIX) was initiated with a Market Perform rating at Wachovia.
• Goldman started Quest Diagnostics (NASDAQ: DGX) with a Sell rating and $55 target, LabCorp (NASDAQ: LH) with a Neutral rating and $77 target and Pinnacle Entertainment (NASDAQ: PNK) with a Buy rating and $35 target.

MOST NOTEWORTHY: Gen-Probe, Monster Worldwide, LabCorp and Quest Diagnostics were today's noteworthy initiations:

• Deutsche Bank initiated shares of Gen-Probe (NASDAQ: GPRO) with a Buy rating and $78 target and expects the company's broad product portfolio in Clinical Diagnostics and Blood Screening to drive growth.
  
• CIBC initiated Monster Worldwide (NASDAQ: MNST) with a Sector Performer rating, as they believe their macro concerns are more important than the company's intermediate-term prospects and its position within the global recruiting market.
  
• William Blair views the valuation of LabCorp (NYSE: LH) as compelling given the company's growth outlook. The firm started shares off with an Outperform rating.
  
• William Blair also initiated Quest Diagnostics (NYSE: DGX) with a Market Perform rating, and prefers a wait-and-see approach as the company's diversification strategy unfolds.

OTHER INITIATIONS:

• Wachovia initiated Cleco (NYSE: CNL), ITC Holdings (NYSE: ITC) and Aqua America (NYSE: WTR) with Outperform ratings and American States Water (NYSE: AWR) with a Market Perform rating.
  
• Baird resumed coverage of Ritchie Bros (NYSE: RBA) with a Neutral rating and $78 target.

It's not a glamorous business, but it's a necessary (and evidently a profitable) one. Laboratory Corp. of America Holdings (NYSE: LH) earned an unlikely distinction as the top performer in 2000 among our basket of hundreds of stocks. The company provides mostly routine laboratory and testing services, analyzing close to 400,000 specimens each day.

1999 was a very good year for the market and for our faux portfolio, with Qualcomm (NASDAQ: QCOM) shares leaping almost 2600% to turn just over $6,500 into more than $175,000. With $175,327 at his disposal, our happy investor scooped up 19,016 shares of LH, trading at $9.22 at the beginning of the 'aughts. Though the market proceeded to tumble, with the tech bubble showing signs of initial weakness as early as March, LabCorp. shares continued higher for the entire year. In fact, the stock peaked on December 28, 2000, before embarking upon a months-long pullback.



By the end of 2000, hanging chads made for a very interesting election outcome and LH shares had gained a total of 377%, closing the year at $44. Our hypothetical hindsight portfolio was now worth $836,704. After four years of absolutely brilliant (read: highly improbable) stock picking, we were closing in on the million-dollar mark.

Next: Step 5: NVIDIA (NVDA), 2001

Beth Gaston Moon is an analyst at Schaeffer's Investment Research.

MOST NOTEWORTHY: Taser Int'l (TASR), Motorola (MOT), Advantest (ATE), STMicroelectronics (STM) and Joy Global (JOYG) were today's noteworthy upgrades:

• Merriman upgraded shares of Taser Int'l (NASDAQ: TASR) to Buy from Hold on valuation following the 25% decline in price since late July, accelerating law enforcement demand and upside potential from the recently launched personal TASER C2.

• Lehman upgraded shares of Motorola (NYSE: MOT) to Overweight from Equal Weight as they believe increased production and opex progress in Q3 could signal a turnaround at the company's phone unit.

• Jefferies upgraded Advantest (NYSE: ATE) to Hold from Underperform on valuation.

• STMicroelectronics (NYSE: STM) was upgraded to Market Perform from Underperform on valuation at Bernstein.

• Stifel upgraded shares of Joy Global (NASDAQ: JOYG) to Buy from Hold following the in line Q3 report as they believe bad news is reflected in valuation...

OTHER UPGRADES:

• Idacorp (NYSE: IDA) was upgraded to Market Perform from Under Perform at Wachovia.

• UBS upgraded TDK Corp (NYSE: TDK) to Neutral from Sell.

• Wedbush raised Big Lots (NYSE: BIG) to Buy from Hold, with a $35 target, and DSW Inc. (NYSE: DSW) to Hold from Sell, with a $29 target.

• LabCorp (NYSE: LH) was upgraded to Outperform from Neutral at Cowen.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).

MOST NOTEWORTHY: Old Dominion Freight (ODFL), Jamba (JMBA), AMD (AMD), Orbitz Worldwide (OWW) and Quest Diagnostics (DGX) were today's notable initiations:

• Baird is positive on Old Dominion's (NASDAQ: ODFL) growth opportunities, valuation, 2008 improving truck fundamentals, and a potentially seasonally stronger Q4, starting shares with an Overweight rating and $36 target.

• Merriman initiated Jamba (NASDAQ: JMBA) with a Buy rating, as the company aggressively expands its store base beyond California.

• BMO Capital believes AMD (NYSE: AMD) may lose the Intel platform integrated graphics market, and sizeable Intel platform discrete graphics market share. The firm initiated AMD shares with an Underperform rating and $10 target.

• Soleil has concerns regarding Orbitz Worldwide's (NYSE: OWW) decelerating growth and poorer business mix vs. competitors and started shares with a Hold rating and $13 target.

• Credit Suisse initiated Quest Diagnostics (NYSE: DGX) with a Neutral rating and $61 target, citing the recent UnitedHealth (UNH) contract loss, slowing growth, and valuation for its Neutral rating...

OTHER INITIATIONS:

• McDermott (NYSE: MDR) and Capella Education (NASDAQ: CPLA) were initiated with Buy ratings at Citigroup.

• JMP Securities started ShoreTel (NASDAQ: SHOR) with a Market Outperform rating.

• Credit Suisse initiated LabCorp (NYSE: LH) with an Outperform rating.

• FTN Midwest started Northwest Airlines (NYSE: NWA) with a Buy rating.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).

Looks like we still might have a summer swoon, and if we do, then many of the stocks on your watch list might pop up as buy opportunities. One more stock you might want to add to that list is Quest Diagnostics Inc. (NYSE: DGX), the world's leading clinical lab. It operates 2,000 patient services centers where samples are collected, along with about 30 primary labs and 150 rapid response labs throughout the US and in Mexico and the UK.

Investment ideas come from many different avenues. This one came to me because I donated blood this week. Not everyone is eligible to donate and only 5% of that group actually do. Our whole blood supply is supported by very few people. I started thinking about the cost of collecting, maintaining and distributing the blood and how quality control is done. According to the PBS series Red Gold: The Epic Story of Blood: "Currently, the average base price of a unit of RBCs [red blood cells] is in the range of $100-$160, but will increase as more sophisticated testing for transmissible diseases (e.g., HIV and viral hepatitis) are introduced." The news of globe-trotting tuberculosis patient Andrew Speaker also brought the the idea of labs and screening to mind.

Quest runs many different tests and screens for many different things. Ironically, now I'm screening the (blood) screener, and it did not take long to discover there was some value here. You can see some of my often repeated criteria; low P/S, fair P/B, pays a dividend (wish it was higher), not much debt, good cash-flow, and ROE is solid and higher than the P/E.

• Price-to-earnings P/E: 17.69 (TTM)
• Price-to-sales P/S: 1.55 (TTM)
• Price-to-book P/B: 3.13 (TTM)
• Price-to-cash-flow P/CF: 9.95 (TTM)
• Return-on-equity ROE: 20.2 (TTM)
• Long Term Debt-to-Equity (MRQ) 0.5
• Dividend Yield 0.82%

Quest has been building shareholder value for quite some time and the stock price is nearing a two year low, and 20%+ below its all time high set last year.

MOST NOTEWORTHY: The semiconductor sector, Quest Diagnostics (NYSE: DGX) and Federal National Mortgage Association (NYSE: FNM) were today's noteworthy upgrades:

• Bernstein upgraded the semiconductor sector to Overweight form Market Weight on expectations that utilization will rise starting in Q2. The firm upgraded ASML Holding NV (NASDAQ: ASML) to Outperform from Market Perform and Infineon Technologies (NYSE: IFX) to Market Perform from Underperform.
• UBS upgraded Quest Diagnostics to Buy from Neutral, citing Laboratory Corporation Of America Holdings' (NYSE: LH) contract renewal with Cigna HealthCare, which should ease concerns regarding deteriorating pricing.
• Fannie Mae was upgraded to Outperform from Market Perform at Friedman Billings, citing improving fundamentals, better business mix and the possibility the company reports current financials in the next 12-18 months.

OTHER UPGRADES:

• Mediacom Communications Corporation (NASDAQ: MCCC) was upgraded to Neutral at Pali Capital, as the firm does not see a major catalyst to drive down shares.
• Soleil upgraded shares of ICU Medical Inc (NASDAQ: ICUI) to Buy from Hold.
• DynCorp International Inc (NYSE: DCP) was upgraded to Outperformer from Sector Performer at CIBC World Markets.
• CIBC also upgraded shares of Radware Limited (NASDAQ: RDWR) to Outperformer from Sector Performer.